会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明授权
    • Polymeric drug delivery compositions and methods for treating ophthalmic diseases
    • 聚合物药物递送组合物和治疗眼科疾病的方法
    • US08173163B2
    • 2012-05-08
    • US12390255
    • 2009-02-20
    • Joachim B. KohnIsaac John KhanCarmine P. Lovine
    • Joachim B. KohnIsaac John KhanCarmine P. Lovine
    • A61K9/14
    • A61K9/0051A61K31/00A61K47/14A61K47/34
    • Degradable polymeric compositions containing water-insoluble drugs blended with copolymers of biocompatible diphenol compound monomer units with pendant carboxylic acid groups polymerized with biocompatible diphenol com-pound monomer units with pendant carboxylic acid ester groups and poly(alkylene oxide) blocks, wherein the molar fraction in the copolymer of biocompatible diphenol compound monomer units with pendant carboxylic acid groups and poly(alkylene oxide) blocks relative to the weight percentage of the drug in the composition is effective to provide pseudo-zero order release of the drug from the composition during the sustained-release phase of drug delivery under physiological conditions. Ocular treatment methods and manufacturing methods are also disclosed.
    • 可降解的聚合物组合物含有与生物相容性双酚化合物单体单元与侧链羧酸基团的共聚物共混物的水不溶性药物,其与具有侧链羧酸酯基团和聚(环氧烷)嵌段的生物相容性双酚单体单元聚合的侧链羧酸基团,其中摩尔分数 生物相容性双酚化合物单体单元与侧链羧酸基团和聚(环氧烷)嵌段的共聚物相对于组合物中药物的重量百分比是有效的,以提供药物在组合物中的假零级释放, 生理条件下药物释放期。 还公开了眼部治疗方法和制造方法。
    • 28. 发明授权
    • Polymeric drug formulations
    • 聚合药物制剂
    • US07005454B2
    • 2006-02-28
    • US09257145
    • 1999-02-24
    • Stephen BrocchiniStephen R. HansonJoachim B. Kohn
    • Stephen BrocchiniStephen R. HansonJoachim B. Kohn
    • A61K47/30A61K47/32A61K47/34
    • A61K9/146A61K9/2031A61K9/204A61K9/7007
    • Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.
    • 含水溶性药物的非释放单相分散体在水不溶性组织相容的聚合物基质中的聚合药物制剂。 还公开了含有水溶性药物和水不溶性组织相容聚合物基质的单相分散体的聚合药物制剂,以及与组织相容的聚合物不可混溶的第二种相位破坏性聚合物,并且是 存在的量足以在组织相容性聚合物基质中形成第二聚合物的相分离微区,使得来自组织相容性聚合物基质的水溶性药物的释放速率与第二聚合物的量相关 。 还描述了制备聚合物药物制剂的方法,以及利用聚合物药物制剂的用于位点特异性药物递送的方法。